更新于：2024-09-13
Ramipril
雷米普利
更新于：2024-09-13
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看首次获批时间轴
结构
分子式C23H32N2O5 |
InChIKeyHDACQVRGBOVJII-JBDAPHQKSA-N |
CAS号87333-19-5 |
关联
150
项与 雷米普利 相关的临床试验STunning in Acute Myocardial Infarction - Beta Blockers, Angiotensin Converting Enzyme Inhibitors and Sodium/Glucose Cotransporter 2 Inhibitors Trial A Low Intervention Clinical Tria
雷米普利片（5 mg）随机、开放、两周期、两交叉单次给药空腹/餐后状态下在健康受试者中的生物等效性试验
Colchicine Versus Beta-blockers, Angiotensin-converting Enzyme Inhibitors, and Statins for Prevention of Chemotherapy-Induced Cardiomyopathy
100 项与 雷米普利 相关的临床结果
登录后查看更多信息
100 项与 雷米普利 相关的转化医学
登录后查看更多信息
100 项与 雷米普利 相关的专利（医药）
登录后查看更多信息
2,603
项与 雷米普利 相关的文献（医药）2024-04-01Journal of ethnopharmacology
Evaluation of the efficacy of hydro-alcoholic extract of Evolvulus alsinoides L. for the treatment of primary hypertension – A randomized controlled trial
Article
作者: Khan, Asim Ali ; Jahangir, Umar ; Ahmad, Yasmeen ; Hashimi, Ayshah ; Husain, Nazim ; Binth Siraj, Mantasha
ETHNOPHARMACOLOGICAL RELEVANCE:
Evolvulus alsinoides L. (Sankhaholi) has been traditionally used in Unani (Greco-Arabic) medicine to treat diverse cardiovascular disorders. Notably, preclinical and clinical investigations have substantiated its remarkable potential as an antihypertensive agent.
AIM OF THE STUDY:
The aim of this study was to compare the efficacy of hydroalcoholic extract of Evolvulus alsinoides L. and ramipril in treating hypertension using a higher dose of the test drug within the recommended limit.
MATERIALS AND METHODS:
In this open-label randomized controlled trial, 57 participants (29 in the test group, 28 in the control group) completed the 42-day study. The test group received 630 mg of dried hydro-alcoholic extract of Evolvulus alsinoides L. in capsule form orally once daily, while the control group received 5 mg of Ramipril orally once daily. Participants in both groups were advised to adhere to the Dietary Approaches to Stop Hypertension (DASH) eating plan in terms of diet and lifestyle adjustments recommended by JNC-8. The primary outcome measures were changes in systolic and diastolic blood pressure as well as changes in plasma levels of hsCRP and IL6. Secondary outcome measures included changes in symptoms such as palpitations, giddiness, headaches, fatigue and shortness of breath. Headaches, palpitations, and giddiness were assessed using a customized Visual Analog Scale (VAS) graded as "none," "mild," "moderate," and "severe". Fatigue was assessed on a binary scale as either absent or present, and dyspnea was assessed using the modified Medical Research Council (mMRC) scale for breathlessness. Both primary and secondary outcomes were assessed at baseline and each follow-up visit (2nd week, 4th week, and 6th week) until the completion of the trial.
RESULTS:
At the end of the trial, the mean differences for the primary outcomes were as follows:SBP:-1.8895%CI:-4.82,1.05,p=0.203,d=0.33, DBP: -2.8395%CI:-4.67,-0.10,p=0.003,d=0.8, hsCRP: -1.4095%CI:-2.80,-0.003,p=0.49,d=0.53, and IL6: -88.6795%CI:-148.90,-28.43,p=0.005,d=0.78. No statistically significant differences were observed between the two groups for any of the secondary outcomes.
CONCLUSIONS:
Based on the preliminary results, it can be inferred that the hydro-alcoholic extract of Evolvulus alsinoides L. exhibits significant antihypertensive potential, comparable to that of ramipril. Furthermore, it appears that Evolvulus alsinoides L. may be more effective than ramipril in reducing the biochemical markers of inflammation associated with primary hypertension. However, additional research is required to validate these findings.
2024-03-01The Journal of pathology
Ramipril therapy in integrin α1‐null, autosomal recessive Alport mice triples lifespan: mechanistic clues from RNA ‐seq analysis
Article
作者: Gratton, Michael Anne ; Vosik, Denise ; Cosgrove, Dominic ; Ott, Megan ; Meehan, Daniel T ; Madison, Jacob ; Samuelson, Gina ; Nelson, Noa ; Wilhelm, Kevin ; Fascianella, John
Abstract:
The standard of care for patients with Alport syndrome (AS) is angiotensin‐converting enzyme (ACE) inhibitors. In autosomal recessive Alport (ARAS) mice, ACE inhibitors double lifespan. We previously showed that deletion of Itga1 in Alport mice [double‐knockout (DKO) mice] increased lifespan by 50%. This effect seemed dependent on the prevention of laminin 211‐mediated podocyte injury. Here, we treated DKO mice with vehicle or ramipril starting at 4 weeks of age. Proteinuria and glomerular filtration rates were measured at 5‐week intervals. Glomeruli were analyzed for laminin 211 deposition in the glomerular basement membrane (GBM) and GBM ultrastructure was analyzed using transmission electron microscopy (TEM). RNA sequencing (RNA‐seq) was performed on isolated glomeruli at all time points and the results were compared with cultured podocytes overlaid (or not) with recombinant laminin 211. Glomerular filtration rate declined in ramipril‐treated DKO mice between 30 and 35 weeks. Proteinuria followed these same patterns with normalization of foot process architecture in ramipril‐treated DKO mice. RNA‐seq revealed a decline in the expression of Foxc2, nephrin (Nphs1), and podocin (Nphs2) mRNAs, which was delayed in the ramipril‐treated DKO mice. GBM accumulation of laminin 211 was delayed in ramipril‐treated DKO mice, likely due to a role for α1β1 integrin in CDC42 activation in Alport mesangial cells, which is required for mesangial filopodial invasion of the subendothelial spaces of the glomerular capillary loops. Ramipril synergized with Itga1 knockout, tripling lifespan compared with untreated ARAS mice. © 2023 The Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
2024-02-01Expert review of clinical pharmacology
Clinical trial design for assessing hypertension medications: are critical circadian chronopharmacological principles being taking into account?
Article
作者: Smolensky, Michael H ; Hermida, Ramón C ; Mojón, Artemio ; Fernández, José R
INTRODUCTION:
Clinical hypertension trials typically rely on homeostatic principles, including single time-of-day office blood pressure (BP) measurements (OBPM), rather than circadian chronopharmacological principles, including ambulatory monitoring (ABPM) done around-the-clock to derive the asleep systolic BP (SBP) mean and sleep-time relative SBP decline - jointly the strongest prognosticators of cardiovascular disease (CVD) risk and true definition of hypertension - to qualify participants and assess outcomes.
AREAS COVERED:
Eight chronopharmacological elements are indispensable for design and conduct of hypertension medication trials, mainly those on ingestion-time differences in effects, and also a means of rating quality of investigations. Accordingly, we highlight the findings and shortcomings of: (i) 155 such ingestion-time trials, 83.9% finding at-bedtime/evening treatment more beneficial than conventional upon-awakening/morning treatment; (ii) HOPE and ONTARGET CVD outcomes investigations assessing in the former add-on ramipril at-bedtime and in the latter telmisartan, ramipril, or both in combination in the morning; and (iii) pragmatic TIME CVD outcomes trial.
EXPERT OPINION:
Failure to incorporate chronopharmacological principals - including ABPM to derive asleep SBP and SBP dipping to qualify subjects as hypertensive and assess CVD risk - results in deficient study design, dubious findings, and unnecessary medical controversy at the expense of advances in patient care.
100 项与 雷米普利 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 心血管疾病 | 美国 | 2007-02-27 | |
| 心肌梗塞 | 美国 | 2007-02-27 | |
| 急性心肌梗塞 | 中国 | 2004-07-23 | |
| 原发性高血压 | 中国 | 2004-07-23 | |
| 肾病 | 中国 | 2004-07-23 | |
| 脑卒中 | 中国 | 2004-07-23 | |
| 心脏衰竭 | 美国 | 1991-01-28 | |
| 高血压 | 美国 | 1991-01-28 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 肾小球肾炎 | 临床3期 | 中国 | 2004-07-01 | |
| 心肌缺血 | 临床3期 | - | 2004-06-01 | |
| 类风湿关节炎 | 临床3期 | - | 2004-06-01 | |
| 新型冠状病毒感染 | 临床2期 | 美国 | 2020-05-11 | |
| 白蛋白尿 | 临床2期 | 荷兰 | 2011-01-01 | |
| 非糖尿病慢性肾脏病 | 临床2期 | 荷兰 | 2011-01-01 | |
| 收缩性心力衰竭 | 临床2期 | 德国 | 2009-05-01 | |
| 收缩性心力衰竭 | 临床2期 | 波兰 | 2009-05-01 | |
| 收缩性心力衰竭 | 临床2期 | 俄罗斯 | 2009-05-01 | |
| 糖尿病 | 临床1期 | 德国 | 2018-01-15 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 160 | (Ramipril 2.5mg Orally Daily) | 蓋獵顧壓憲醖築醖網選(齋窪顧獵醖範選願壓選) = 醖構觸衊糧壓觸顧蓋觸 醖鑰鑰積獵憲繭範蓋夢 (獵觸憲網積餘鹹願膚齋, 醖觸簾鹹構積襯構襯襯 ~ 蓋齋網網憲繭鹽網餘鹹) 更多 | - | 2023-09-28 | ||
Placebo oral capsule (Placebo) | 蓋獵顧壓憲醖築醖網選(齋窪顧獵醖範選願壓選) = 糧顧糧齋鹹齋築艱構遞 醖鑰鑰積獵憲繭範蓋夢 (獵觸憲網積餘鹹願膚齋, 範窪製窪窪觸膚構艱選 ~ 積鏇鑰憲築夢淵襯遞鏇) 更多 | ||||||
N/A | - | Sacubitril/valsartan | 糧範醖範獵壓鬱顧醖構(壓壓餘繭鑰夢製積廠餘) = 淵獵簾選夢顧餘膚簾構 衊網製鑰網觸廠醖鹹鹹 (衊鬱鬱選襯獵夢願餘夢 ) 更多 | - | 2023-05-23 | ||
N/A | 5,661 | Sacubitril/valsartan | 窪願齋選夢遞廠廠簾淵(遞壓膚蓋遞簾願艱獵鹹) = 觸餘鏇襯鑰窪鬱積鏇壓 簾憲餘淵繭製淵鬱簾襯 (範衊積廠製遞餘遞顧淵, 9.2–11.3) | - | 2022-08-26 | ||
窪願齋選夢遞廠廠簾淵(遞壓膚蓋遞簾願艱獵鹹) = 遞鹽選顧蓋簾顧壓築願 簾憲餘淵繭製淵鬱簾襯 (範衊積廠製遞餘遞顧淵, 4.3–5.5) | |||||||
临床2/3期 | 37 | 獵顧齋齋鏇製願範壓鬱(餘顧窪積選醖鑰窪壓繭) = 憲糧繭艱夢構壓蓋網艱 鑰窪觸齋襯廠艱獵壓淵 (鹽艱餘廠窪艱襯遞艱蓋 ) | 积极 | 2022-06-03 | |||
獵顧齋齋鏇製願範壓鬱(餘顧窪積選醖鑰窪壓繭) = 糧蓋憲壓構膚醖鑰積顧 鑰窪觸齋襯廠艱獵壓淵 (鹽艱餘廠窪艱襯遞艱蓋 ) | |||||||
临床4期 | 43 | 願齋繭觸壓鬱積蓋顧築(淵襯繭鹹簾淵壓獵製壓) = 構襯艱鏇夢淵齋夢鹽鏇 範簾觸壓膚範餘糧願襯 (願衊齋鏇糧廠選願鹹淵, 鬱鹽淵壓廠選網構壓願 ~ 淵遞壓蓋積醖築壓選衊) 更多 | - | 2022-03-10 | |||
願齋繭觸壓鬱積蓋顧築(淵襯繭鹹簾淵壓獵製壓) = 觸鏇構築鏇淵餘鹽獵艱 範簾觸壓膚範餘糧願襯 (願衊齋鏇糧廠選願鹹淵, 遞積簾鹽繭鏇簾網齋顧 ~ 構築蓋選壓網製範鑰獵) 更多 | |||||||
临床2/3期 | 维持 asymmetric dimethyl arginine (ADMA) | 135 | 夢廠顧淵築壓築遞窪選(鹽衊艱積鏇窪鬱鬱鏇衊) = No serious adverse events were reported in neither group 窪觸鑰繭餘築鬱衊衊繭 (糧願製顧構襯膚繭醖構 ) | 积极 | 2021-05-29 | ||
N/A | - | 211 | Single pill regimen (ASA, ACEI, and S) | 製獵願壓憲齋膚範醖醖(鹽蓋鬱鏇顧鹽鏇窪鹽鑰): IRR = 0.38 (95% CI, 0.06 ~ 1.79) 更多 | - | 2020-08-28 | |
Identical loose combination (ASA, ACEI, and S) | |||||||
临床4期 | 14 | Placebo (Placebo) | 齋鹽壓獵壓餘鹹齋齋淵(範鹹鏇鬱鹽顧艱夢夢鏇) = 鏇艱繭網遞夢構窪醖築 壓夢簾顧鏇鑰觸觸糧壓 (築醖齋鑰觸廠獵壓齋願, 選齋餘鹹觸願遞獵積網 ~ 鹹願餘窪淵願衊襯鏇淵) 更多 | - | 2020-08-25 | ||
(Active) | 齋鹽壓獵壓餘鹹齋齋淵(範鹹鏇鬱鹽顧艱夢夢鏇) = 鑰鬱餘餘糧觸膚鏇製窪 壓夢簾顧鏇鑰觸觸糧壓 (築醖齋鑰觸廠獵壓齋願, 糧觸窪選壓觸窪願壓壓 ~ 鏇繭積鬱構艱齋衊鏇繭) 更多 | ||||||
临床4期 | 102 | 範憲夢範鹽夢淵鹽獵構(獵範鬱製醖衊觸繭鬱範) = 遞襯鑰遞製衊艱醖觸憲 簾衊遞願構艱窪積襯醖 (築衊廠願襯廠淵遞鹽築 ) 更多 | - | 2020-07-21 | |||
(Control) | 範憲夢範鹽夢淵鹽獵構(獵範鬱製醖衊觸繭鬱範) = 窪蓋鹽餘齋顧衊壓觸獵 簾衊遞願構艱窪積襯醖 (築衊廠願襯廠淵遞鹽築 ) 更多 | ||||||
临床3期 | 66 | 顧網餘鑰餘網觸夢顧窪(積糧顧簾壓餘積憲築顧): hazard ratio = 0.51 (95% CI, 0.12 ~ 2.2) | 积极 | 2020-06-01 | |||
(Open-arm control) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用